Literature DB >> 22520759

Small-molecule inhibitors of the c-Fes protein-tyrosine kinase.

Sabine Hellwig1, Chandra V Miduturu, Shigeru Kanda, Jianming Zhang, Panagis Filippakopoulos, Eidarus Salah, Xianming Deng, Hwan Geun Choi, Wenjun Zhou, Wooyoung Hur, Stefan Knapp, Nathanael S Gray, Thomas E Smithgall.   

Abstract

The c-Fes protein-tyrosine kinase modulates cellular signaling pathways governing differentiation, the innate immune response, and vasculogenesis. Here, we report the identification of types I and II kinase inhibitors with potent activity against c-Fes both in vitro and in cell-based assays. One of the most potent inhibitors is the previously described anaplastic lymphoma kinase inhibitor TAE684. The crystal structure of TAE684 in complex with the c-Fes SH2-kinase domain showed excellent shape complementarity with the ATP-binding pocket and a key role for the gatekeeper methionine in the inhibitory mechanism. TAE684 and two pyrazolopyrimidines with nanomolar potency against c-Fes in vitro were used to establish a role for this kinase in osteoclastogenesis, illustrating the value of these inhibitors as tool compounds to probe the diverse biological functions associated with this unique kinase.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22520759      PMCID: PMC3334838          DOI: 10.1016/j.chembiol.2012.01.020

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  54 in total

1.  Src homology 2 domain substitution modulates the kinase and transforming activities of the Fes protein-tyrosine kinase.

Authors:  J A Rogers; H Y Cheng; T E Smithgall
Journal:  Cell Growth Differ       Date:  2000-11

2.  The nonreceptor protein-tyrosine kinase c-Fes is involved in fibroblast growth factor-2-induced chemotaxis of murine brain capillary endothelial cells.

Authors:  S Kanda; E C Lerner; S Tsuda; T Shono; H Kanetake; T E Smithgall
Journal:  J Biol Chem       Date:  2000-04-07       Impact factor: 5.157

3.  c-fes expression in ontogenetic development and hematopoietic differentiation.

Authors:  A Carè; G Mattia; E Montesoro; I Parolini; G Russo; M P Colombo; C Peschle
Journal:  Oncogene       Date:  1994-03       Impact factor: 9.867

4.  An identity crisis for fps/fes: oncogene or tumor suppressor?

Authors:  Waheed Sangrar; Ralph A Zirgnibl; Yan Gao; William J Muller; Zongchao Jia; Peter A Greer
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

5.  The Fes tyrosine kinase: a signal transducer that regulates myeloid-specific gene expression through transcriptional activation.

Authors:  Jynho Kim; Yoshiyasu Ogata; Humayra Ali; Ricardo A Feldman
Journal:  Blood Cells Mol Dis       Date:  2004 Mar-Apr       Impact factor: 3.039

6.  Bimolecular fluorescence complementation demonstrates that the c-Fes protein-tyrosine kinase forms constitutive oligomers in living cells.

Authors:  Jonathan M Shaffer; Sabine Hellwig; Thomas E Smithgall
Journal:  Biochemistry       Date:  2009-06-09       Impact factor: 3.162

7.  Downregulation of the c-Fes protein-tyrosine kinase inhibits the proliferation of human renal carcinoma cells.

Authors:  Shigeru Kanda; Yasuyoshi Miyata; Hiroshi Kanetake; Thomas E Smithgall
Journal:  Int J Oncol       Date:  2009-01       Impact factor: 5.650

8.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.

Authors:  Wenjun Zhou; Dalia Ercan; Liang Chen; Cai-Hong Yun; Danan Li; Marzia Capelletti; Alexis B Cortot; Lucian Chirieac; Roxana E Iacob; Robert Padera; John R Engen; Kwok-Kin Wong; Michael J Eck; Nathanael S Gray; Pasi A Jänne
Journal:  Nature       Date:  2009-12-24       Impact factor: 49.962

Review 9.  The contrasting oncogenic and tumor suppressor roles of FES.

Authors:  Peter A Greer; Shigeru Kanda; Thomas E Smithgall
Journal:  Front Biosci (Schol Ed)       Date:  2012-01-01

10.  Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation.

Authors:  Panagis Filippakopoulos; Michael Kofler; Oliver Hantschel; Gerald D Gish; Florian Grebien; Eidarus Salah; Philipp Neudecker; Lewis E Kay; Benjamin E Turk; Giulio Superti-Furga; Tony Pawson; Stefan Knapp
Journal:  Cell       Date:  2008-09-05       Impact factor: 41.582

View more
  17 in total

1.  A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant BtkC481S mutation in B-cell malignancies.

Authors:  Fu Gui; Jie Jiang; Zhixiang He; Li Li; Yunzhan Li; Zhou Deng; Yue Lu; Xinrui Wu; Guyue Chen; Jingyi Su; Siyang Song; Yue-Ming Zhang; Cai-Hong Yun; Xin Huang; Ellen Weisberg; Jianming Zhang; Xianming Deng
Journal:  Br J Pharmacol       Date:  2019-12-09       Impact factor: 8.739

2.  Potent Pyrimidine and Pyrrolopyrimidine Inhibitors of Testis-Specific Serine/Threonine Kinase 2 (TSSK2).

Authors:  Jon E Hawkinson; Rondedrick Sinville; Deepti Mudaliar; Jagathpala Shetty; Timothy Ward; John C Herr; Gunda I Georg
Journal:  ChemMedChem       Date:  2017-10-20       Impact factor: 3.466

3.  High-resolution structural analysis shows how different crystallographic environments can induce alternative modes of binding of a phosphotyrosine peptide to the SH2 domain of Fer tyrosine kinase.

Authors:  Yoshiyuki Matsuura
Journal:  Protein Sci       Date:  2019-08-31       Impact factor: 6.725

4.  Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma.

Authors:  Michael Olvedy; Julie C Tisserand; Flavie Luciani; Bram Boeckx; Jasper Wouters; Sophie Lopez; Florian Rambow; Sara Aibar; Bernard Thienpont; Jasmine Barra; Corinna Köhler; Enrico Radaelli; Sophie Tartare-Deckert; Stein Aerts; Patrice Dubreuil; Joost J van den Oord; Diether Lambrechts; Paulo De Sepulveda; Jean-Christophe Marine
Journal:  J Clin Invest       Date:  2017-05-02       Impact factor: 14.808

5.  A Discovery Strategy for Selective Inhibitors of c-Src in Complex with the Focal Adhesion Kinase SH3/SH2-binding Region.

Authors:  Jamie A Moroco; Matthew P Baumgartner; Heather L Rust; Hwan Geun Choi; Wooyoung Hur; Nathanael S Gray; Carlos J Camacho; Thomas E Smithgall
Journal:  Chem Biol Drug Des       Date:  2014-11-28       Impact factor: 2.817

6.  Stromal expression of Fer suppresses tumor progression in renal cell carcinoma and is a predictor of survival.

Authors:  Kensuke Mitsunari; Yasuyoshi Miyata; Shin-Ichi Watanabe; Akihiro Asai; Takuji Yasuda; Shigeru Kanda; Hideki Sakai
Journal:  Oncol Lett       Date:  2016-12-12       Impact factor: 2.967

Review 7.  Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments.

Authors:  Muhammad Latif; Zaman Ashraf; Sulman Basit; Abdul Ghaffar; Muhammad Sohail Zafar; Aamer Saeed; Sultan Ayoub Meo
Journal:  RSC Adv       Date:  2018-05-04       Impact factor: 4.036

8.  FER-mediated phosphorylation and PIK3R2 recruitment on IRS4 promotes AKT activation and tumorigenesis in ovarian cancer cells.

Authors:  Yanchun Zhang; Xuexue Xiong; Qi Zhu; Jiali Zhang; Shengmiao Chen; Yuetong Wang; Jian Cao; Li Chen; Linjun Hou; Xi Zhao; Piliang Hao; Jian Chen; Min Zhuang; Dake Li; Gaofeng Fan
Journal:  Elife       Date:  2022-05-12       Impact factor: 8.713

9.  FES-related tyrosine kinase activates the insulin-like growth factor-1 receptor at sites of cell adhesion.

Authors:  Joanna Stanicka; Leonie Rieger; Sandra O'Shea; Orla Cox; Michael Coleman; Ciara O'Flanagan; Barbara Addario; Nuala McCabe; Richard Kennedy; Rosemary O'Connor
Journal:  Oncogene       Date:  2018-03-15       Impact factor: 9.867

10.  HGF-independent regulation of MET and GAB1 by nonreceptor tyrosine kinase FER potentiates metastasis in ovarian cancer.

Authors:  Gaofeng Fan; Siwei Zhang; Yan Gao; Peter A Greer; Nicholas K Tonks
Journal:  Genes Dev       Date:  2016-07-01       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.